TG Therapeutics, Inc. (TGTX)
USD 37.19
(-5.46%)
USD 37.19
(-5.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 169.08 Million USD | 25.26% |
| 2022 | 134.98 Million USD | -5.26% |
| 2021 | 142.47 Million USD | 34.04% |
| 2020 | 106.29 Million USD | -14.56% |
| 2019 | 124.39 Million USD | 108.79% |
| 2018 | 59.58 Million USD | -38.82% |
| 2017 | 97.38 Million USD | 77.76% |
| 2016 | 54.78 Million USD | -51.72% |
| 2015 | 113.47 Million USD | 30.81% |
| 2014 | 86.74 Million USD | 80.3% |
| 2013 | 48.11 Million USD | 637.5% |
| 2012 | 6.52 Million USD | 4.03% |
| 2011 | 6.27 Million USD | -73.87% |
| 2010 | 23.99 Million USD | 235.63% |
| 2009 | 7.15 Million USD | 27.12% |
| 2008 | 5.62 Million USD | 200.53% |
| 2007 | 1.87 Million USD | -3.69% |
| 2006 | 1.94 Million USD | 16.66% |
| 2005 | 1.66 Million USD | 39.32% |
| 2004 | 1.19 Million USD | 23.78% |
| 2003 | 966.02 Thousand USD | 67.21% |
| 2002 | 577.73 Thousand USD | 13.59% |
| 2001 | 508.61 Thousand USD | -75.55% |
| 2000 | 2.08 Million USD | 246.74% |
| 1999 | 600 Thousand USD | 0.0% |
| 1998 | 600 Thousand USD | 50.0% |
| 1997 | 400 Thousand USD | 33.33% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 213.21 Million USD | 26.1% |
| 2024 Q2 | 223.63 Million USD | 4.89% |
| 2023 FY | 169.08 Million USD | 25.26% |
| 2023 Q2 | 180.4 Million USD | 6.17% |
| 2023 Q1 | 169.92 Million USD | 25.88% |
| 2023 Q3 | 166.29 Million USD | -7.82% |
| 2023 Q4 | 169.08 Million USD | 1.68% |
| 2022 Q2 | 122.63 Million USD | -7.55% |
| 2022 FY | 134.98 Million USD | -5.26% |
| 2022 Q4 | 134.98 Million USD | 14.97% |
| 2022 Q3 | 117.41 Million USD | -4.26% |
| 2022 Q1 | 132.64 Million USD | -6.9% |
| 2021 Q4 | 142.47 Million USD | 45.13% |
| 2021 Q2 | 98.27 Million USD | -4.97% |
| 2021 FY | 142.47 Million USD | 34.04% |
| 2021 Q1 | 103.41 Million USD | -2.71% |
| 2021 Q3 | 98.17 Million USD | -0.1% |
| 2020 Q2 | 100.39 Million USD | -2.72% |
| 2020 Q4 | 106.29 Million USD | 3.0% |
| 2020 FY | 106.29 Million USD | -14.56% |
| 2020 Q1 | 103.2 Million USD | -17.04% |
| 2020 Q3 | 103.19 Million USD | 2.79% |
| 2019 Q2 | 93.38 Million USD | -4.99% |
| 2019 Q3 | 119.11 Million USD | 27.56% |
| 2019 FY | 124.39 Million USD | 108.79% |
| 2019 Q4 | 124.39 Million USD | 4.43% |
| 2019 Q1 | 98.28 Million USD | 64.96% |
| 2018 Q2 | 140.71 Million USD | 293.48% |
| 2018 Q4 | 59.58 Million USD | 39.76% |
| 2018 FY | 59.58 Million USD | -38.82% |
| 2018 Q1 | 35.76 Million USD | -63.28% |
| 2018 Q3 | 42.63 Million USD | -69.7% |
| 2017 Q2 | 23.22 Million USD | -81.16% |
| 2017 Q4 | 97.38 Million USD | 337.95% |
| 2017 FY | 97.38 Million USD | 77.76% |
| 2017 Q1 | 123.25 Million USD | 125.0% |
| 2017 Q3 | 22.23 Million USD | -4.25% |
| 2016 Q1 | 10.61 Million USD | -90.64% |
| 2016 FY | 54.78 Million USD | -51.72% |
| 2016 Q4 | 54.78 Million USD | -27.62% |
| 2016 Q3 | 75.68 Million USD | 370.21% |
| 2016 Q2 | 16.09 Million USD | 51.61% |
| 2015 FY | 113.47 Million USD | 30.81% |
| 2015 Q4 | 113.47 Million USD | 922.71% |
| 2015 Q3 | 11.09 Million USD | 4.13% |
| 2015 Q2 | 10.65 Million USD | -90.91% |
| 2015 Q1 | 117.26 Million USD | 35.19% |
| 2014 FY | 86.74 Million USD | 80.3% |
| 2014 Q1 | 3.74 Million USD | -92.22% |
| 2014 Q3 | 77.54 Million USD | 37.73% |
| 2014 Q4 | 86.74 Million USD | 11.87% |
| 2014 Q2 | 56.3 Million USD | 1404.45% |
| 2013 FY | 48.11 Million USD | 637.5% |
| 2013 Q2 | 17.85 Million USD | 167.04% |
| 2013 Q3 | 9.66 Million USD | -45.9% |
| 2013 Q4 | 48.11 Million USD | 397.98% |
| 2013 Q1 | 6.68 Million USD | 2.51% |
| 2012 Q1 | 5.88 Million USD | -6.13% |
| 2012 Q2 | 6.74 Million USD | 14.56% |
| 2012 Q3 | 7.33 Million USD | 8.8% |
| 2012 Q4 | 6.52 Million USD | -11.1% |
| 2012 FY | 6.52 Million USD | 4.03% |
| 2011 Q4 | 6.27 Million USD | -65.84% |
| 2011 FY | 6.27 Million USD | -73.87% |
| 2011 Q1 | 19.95 Million USD | -16.85% |
| 2011 Q2 | 20.51 Million USD | 2.77% |
| 2011 Q3 | 18.35 Million USD | -10.49% |
| 2010 Q3 | 24.77 Million USD | -2.39% |
| 2010 Q4 | 23.99 Million USD | -3.11% |
| 2010 Q2 | 25.37 Million USD | -8.06% |
| 2010 FY | 23.99 Million USD | 235.63% |
| 2010 Q1 | 27.59 Million USD | 285.97% |
| 2009 FY | 7.15 Million USD | 27.12% |
| 2009 Q4 | 7.15 Million USD | -2.41% |
| 2009 Q3 | 7.32 Million USD | -1.6% |
| 2009 Q2 | 7.44 Million USD | 13.43% |
| 2009 Q1 | 6.56 Million USD | 16.71% |
| 2008 Q4 | 5.62 Million USD | 13.34% |
| 2008 FY | 5.62 Million USD | 200.53% |
| 2008 Q2 | 4.42 Million USD | 147.44% |
| 2008 Q1 | 1.78 Million USD | -4.55% |
| 2008 Q3 | 4.96 Million USD | 12.27% |
| 2007 Q3 | 1.79 Million USD | -29.21% |
| 2007 Q4 | 1.87 Million USD | 4.5% |
| 2007 Q1 | 2.19 Million USD | 12.84% |
| 2007 Q2 | 2.53 Million USD | 15.38% |
| 2007 FY | 1.87 Million USD | -3.69% |
| 2006 Q4 | 1.94 Million USD | 37.41% |
| 2006 Q1 | 2.24 Million USD | 34.89% |
| 2006 Q3 | 1.41 Million USD | -36.15% |
| 2006 Q2 | 2.21 Million USD | -1.43% |
| 2006 FY | 1.94 Million USD | 16.66% |
| 2005 Q1 | 1.27 Million USD | 6.26% |
| 2005 FY | 1.66 Million USD | 39.32% |
| 2005 Q2 | 1.77 Million USD | 39.73% |
| 2005 Q4 | 1.66 Million USD | -7.9% |
| 2005 Q3 | 1.8 Million USD | 1.87% |
| 2004 Q3 | 1.47 Million USD | 136.2% |
| 2004 Q2 | 624.41 Thousand USD | -17.6% |
| 2004 Q1 | 757.78 Thousand USD | -21.56% |
| 2004 FY | 1.19 Million USD | 23.78% |
| 2004 Q4 | 1.19 Million USD | -18.93% |
| 2003 Q1 | 1.06 Million USD | 84.04% |
| 2003 Q4 | 966.02 Thousand USD | -23.67% |
| 2003 FY | 966.02 Thousand USD | 67.21% |
| 2003 Q3 | 1.26 Million USD | 20.03% |
| 2003 Q2 | 1.05 Million USD | -0.84% |
| 2002 Q3 | 503.94 Thousand USD | 17.82% |
| 2002 Q1 | 484.7 Thousand USD | -4.7% |
| 2002 Q2 | 427.73 Thousand USD | -11.75% |
| 2002 FY | 577.73 Thousand USD | 13.59% |
| 2002 Q4 | 577.73 Thousand USD | 14.64% |
| 2001 Q2 | 706.87 Thousand USD | -9.29% |
| 2001 Q3 | 748.35 Thousand USD | 5.87% |
| 2001 Q4 | 508.61 Thousand USD | -32.04% |
| 2001 FY | 508.61 Thousand USD | -75.55% |
| 2001 Q1 | 779.24 Thousand USD | -62.54% |
| 2000 Q1 | 495.94 Thousand USD | -17.34% |
| 2000 Q4 | 2.08 Million USD | 95.94% |
| 2000 Q2 | 542.48 Thousand USD | 9.38% |
| 2000 Q3 | 1.06 Million USD | 95.73% |
| 2000 FY | 2.08 Million USD | 246.74% |
| 1999 Q4 | 600 Thousand USD | 200.0% |
| 1999 Q1 | 300 Thousand USD | -50.0% |
| 1999 Q2 | 400 Thousand USD | 33.33% |
| 1999 Q3 | 200 Thousand USD | -50.0% |
| 1999 FY | 600 Thousand USD | 0.0% |
| 1998 FY | 600 Thousand USD | 50.0% |
| 1998 Q2 | 600 Thousand USD | 200.0% |
| 1998 Q1 | 200 Thousand USD | -50.0% |
| 1998 Q3 | 600 Thousand USD | 0.0% |
| 1998 Q4 | 600 Thousand USD | 0.0% |
| 1997 Q1 | 300 Thousand USD | 0.0% |
| 1997 Q2 | 300 Thousand USD | 0.0% |
| 1997 Q4 | 400 Thousand USD | 33.33% |
| 1997 FY | 400 Thousand USD | 33.33% |
| 1997 Q3 | 300 Thousand USD | 0.0% |
| 1996 Q3 | 400 Thousand USD | 0.0% |
| 1996 FY | 300 Thousand USD | 0.0% |
| 1996 Q4 | 300 Thousand USD | -25.0% |
| 1996 Q2 | 400 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 49.644% |
| Alkermes plc | 933.53 Million USD | 81.888% |
| Agenus Inc. | 462.29 Million USD | 63.425% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 95.826% |
| Aptorum Group Limited | 5.25 Million USD | -3116.538% |
| Ardelyx, Inc. | 130.76 Million USD | -29.306% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 64.655% |
| Bicycle Therapeutics plc | 224.41 Million USD | 24.654% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -29.856% |
| ChromaDex Corporation | 26.5 Million USD | -537.864% |
| Chimerix, Inc. | 19.74 Million USD | -756.343% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -380.668% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -133.005% |
| CRISPR Therapeutics AG | 346.76 Million USD | 51.24% |
| Precision BioSciences, Inc. | 140.92 Million USD | -19.987% |
| Dyadic International, Inc. | 2.34 Million USD | -7123.845% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -939.691% |
| Fortress Biotech, Inc. | 165.93 Million USD | -1.896% |
| Lantern Pharma Inc. | 2.73 Million USD | -6071.702% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -136.549% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -4691.674% |
| Incyte Corporation | 1.59 Billion USD | 89.381% |
| IO Biotech, Inc. | 17.55 Million USD | -863.118% |
| Jaguar Health, Inc. | 45.86 Million USD | -268.65% |
| Novavax, Inc. | 2.57 Billion USD | 93.427% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -368.925% |
| Opthea Limited | 264.6 Million USD | 36.098% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -29.362% |
| ContextLogic Inc. | 206 Million USD | 17.92% |
| MiMedx Group, Inc. | 96.33 Million USD | -75.527% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -252.099% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -4691.454% |
| NextCure, Inc. | 14.99 Million USD | -1027.459% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -4083.201% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -2432.35% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -261.764% |
| Vaxcyte, Inc. | 167.44 Million USD | -0.977% |
| PDS Biotechnology Corporation | 33.25 Million USD | -408.387% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 28.114% |
| Pharming Group N.V. | 244.07 Million USD | 30.724% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1318.26% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -32.314% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2459.072% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2459.072% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -105.118% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -2445.311% |
| Acelyrin, Inc. | 86.35 Million USD | -95.807% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -12914.137% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1075.916% |
| Summit Therapeutics Inc. | 125.25 Million USD | -34.99% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1683.785% |
| Senti Biosciences, Inc. | 52.57 Million USD | -221.632% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -145.845% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -11.598% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -8544.427% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -12560.194% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 25.458% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1705.114% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 25.659% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 65.807% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1449.249% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -514.609% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1296.854% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 65.252% |
| Immix Biopharma, Inc. | 3.72 Million USD | -4443.118% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -347.173% |
| MEI Pharma, Inc. | 8.35 Million USD | -1923.758% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -482.75% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 51.354% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -15.916% |
| Fortress Biotech, Inc. | 165.93 Million USD | -1.896% |
| Precigen, Inc. | 41.64 Million USD | -306.025% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -238.644% |
| AlloVir, Inc. | 45.01 Million USD | -275.619% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -29.729% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -22.703% |
| ImmuCell Corporation | 18.81 Million USD | -798.67% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -499.04% |
| Onconetix, Inc. | 23.18 Million USD | -629.416% |
| PureTech Health plc | 125.58 Million USD | -34.64% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1789.218% |
| Elevation Oncology, Inc. | 34.28 Million USD | -393.218% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -6815.542% |
| Seer, Inc. | 39.36 Million USD | -329.531% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -173.45% |
| Innoviva, Inc. | 568.55 Million USD | 70.26% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -520.997% |
| ESSA Pharma Inc. | 3.49 Million USD | -4737.813% |
| GlycoMimetics, Inc. | 6.9 Million USD | -2349.771% |
| GT Biopharma, Inc. | 6.63 Million USD | -2449.148% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 36.047% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 37.902% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -101.229% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1629.947% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -522.345% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -5141.689% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -129.215% |
| Aptose Biosciences Inc. | 15.8 Million USD | -969.569% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1431.611% |
| Soligenix, Inc. | 7.27 Million USD | -2224.223% |
| Century Therapeutics, Inc. | 175.94 Million USD | 3.897% |
| Kura Oncology, Inc. | 51.66 Million USD | -227.291% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -39.415% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -3991.096% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -2456.527% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 33.062% |
| Autolus Therapeutics plc | 263.9 Million USD | 35.93% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1513.099% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -90.28% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -260.53% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 52.081% |
| GRI Bio, Inc. | 2.69 Million USD | -6169.373% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -20785.392% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -443.839% |
| IGM Biosciences, Inc. | 220.17 Million USD | 23.205% |
| INmune Bio, Inc. | 18.86 Million USD | -796.432% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 34.075% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -534.66% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -6120.005% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -5054.612% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -189.257% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -75.839% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 36.13% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 79.456% |
| Verastem, Inc. | 71.18 Million USD | -137.529% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -243.836% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -338.294% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -245.551% |
| Histogen Inc. | 5.69 Million USD | -2867.966% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -3755.454% |
| Surrozen, Inc. | 8.14 Million USD | -1975.936% |
| Organovo Holdings, Inc. | 2.74 Million USD | -6053.02% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -53773.089% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -200.703% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -924.013% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -230.871% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -20348.677% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -33.427% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1463.634% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -12.059% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -6384.949% |
| Apollomics, Inc. | 14.15 Million USD | -1094.694% |
| Amarin Corporation plc | 279.58 Million USD | 39.523% |
| Mesoblast Limited | 188.79 Million USD | 10.441% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1095.116% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 6.473% |
| Synaptogenix, Inc. | 5.52 Million USD | -2957.889% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -2443.397% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 0.601% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1875.94% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -9521.354% |
| Exelixis, Inc. | 678.44 Million USD | 75.078% |
| Better Therapeutics, Inc. | 23.84 Million USD | -609.19% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -3.072% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 71.545% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1483.163% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -10314.1% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -334.364% |
| Gritstone bio, Inc. | 125.91 Million USD | -34.281% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1052.119% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -3222.802% |
| Avid Bioservices, Inc. | 275.66 Million USD | 38.664% |
| Insmed Incorporated | 1.66 Billion USD | 89.825% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -2097.615% |
| MediWound Ltd. | 27.18 Million USD | -521.933% |
| OmniAb, Inc. | 87.4 Million USD | -93.461% |
| Alector, Inc. | 487.66 Million USD | 65.328% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 58.091% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -817.693% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -340.635% |
| Zai Lab Limited | 240.17 Million USD | 29.6% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 73.164% |
| Aura Biosciences, Inc. | 29.22 Million USD | -478.523% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -77.84% |
| Immunic, Inc. | 25.36 Million USD | -566.529% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -144.215% |
| Veracyte, Inc. | 93.71 Million USD | -80.417% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -6361.831% |
| FibroGen, Inc. | 585.72 Million USD | 71.133% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -872.703% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -25790.555% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2889.767% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 97.792% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1962.515% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -101.239% |
| Galecto, Inc. | 5.89 Million USD | -2767.792% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1941.103% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 93.542% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -486.653% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1239.712% |
| XBiotech Inc. | 8.39 Million USD | -1913.636% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1052.119% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -217.948% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 53.434% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -528.943% |
| Theravance Biopharma, Inc. | 169 Million USD | -0.048% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 86.09% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 66.212% |
| Vaxxinity, Inc. | 30.94 Million USD | -446.423% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 82.613% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2703.548% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 77.311% |
| NexImmune, Inc. | 5.08 Million USD | -3225.674% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -45427.122% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -5398.971% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.621% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -3180.637% |
| Scopus BioPharma Inc. | 7.45 Million USD | -2168.247% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -543.055% |
| Ainos, Inc. | 7.39 Million USD | -2186.718% |
| Pluri Inc. | 34.11 Million USD | -395.676% |
| Prothena Corporation plc | 135.01 Million USD | -25.232% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 30.447% |
| Celularity Inc. | 102.92 Million USD | -64.273% |
| Rallybio Corporation | 9.43 Million USD | -1691.914% |
| Cue Biopharma, Inc. | 24.44 Million USD | -591.696% |
| MeiraGTx Holdings plc | 319.99 Million USD | 47.159% |
| Omeros Corporation | 403.25 Million USD | 58.07% |
| Humacyte, Inc. | 114.67 Million USD | -47.445% |
| Immunocore Holdings plc | 228.15 Million USD | 25.891% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -3368.41% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -120.335% |
| Blueprint Medicines Corporation | 918.64 Million USD | 81.594% |
| CalciMedica, Inc. | 4.02 Million USD | -4097.741% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -868.857% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -9.694% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -97.03% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 39.133% |
| Pulmatrix, Inc. | 15.96 Million USD | -959.231% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -971.99% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -587.17% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 32.584% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -232.936% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 86.033% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -431.998% |
| Nutriband Inc. | 1.07 Million USD | -15571.705% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1490.191% |
| Vor Biopharma Inc. | 59.1 Million USD | -186.08% |
| Roivant Sciences Ltd. | 773.95 Million USD | 78.153% |
| Evogene Ltd. | 17.99 Million USD | -839.883% |
| ProKidney Corp. | 29.21 Million USD | -478.741% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -134.909% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -23884.266% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 91.049% |
| CorMedix Inc. | 11.91 Million USD | -1318.793% |
| BioLineRx Ltd. | 50.7 Million USD | -233.488% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -13.131% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -91.184% |
| Atai Life Sciences N.V. | 49.16 Million USD | -243.934% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -442.769% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -841.348% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -35.663% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2890.538% |
| MediciNova, Inc. | 3.89 Million USD | -4244.923% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -825.023% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -11140.553% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4703.714% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 57.437% |
| Biomea Fusion, Inc. | 30.69 Million USD | -450.945% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 93.788% |
| Mereo BioPharma Group plc | 15.96 Million USD | -959.297% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -441.922% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -188.128% |
| Absci Corporation | 58.3 Million USD | -190.006% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -787.678% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -427.369% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -129.144% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -93.278% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -400.696% |
| Allakos Inc. | 74.79 Million USD | -126.071% |
| Imunon, Inc. | 8.53 Million USD | -1882.14% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -651.455% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -47.271% |
| BioAtla, Inc. | 48.98 Million USD | -245.17% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1483.163% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -5984.383% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -29.464% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1089.483% |
| XOMA Corporation | 145.58 Million USD | -16.146% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -402.258% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -145.91% |
| aTyr Pharma, Inc. | 31.59 Million USD | -435.13% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -173.499% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -276.037% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -249.335% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -5791.463% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1972.624% |
| Akari Therapeutics, Plc | 4.58 Million USD | -3588.591% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -853.498% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 89.749% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -41762.256% |
| UroGen Pharma Ltd. | 243.52 Million USD | 30.567% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 47.34% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -6022.812% |
| Orgenesis Inc. | 35.53 Million USD | -375.827% |
| Entera Bio Ltd. | 1.37 Million USD | -12161.421% |
| GH Research PLC | 6.7 Million USD | -2423.28% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -2386.544% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -798.146% |
| Xencor, Inc. | 283.55 Million USD | 40.37% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -5563.208% |
| Replimune Group, Inc. | 113.21 Million USD | -49.35% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -4400.383% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -63.32% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -41762.256% |
| Portage Biotech Inc. | 4.45 Million USD | -3699.663% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -11140.553% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -633.557% |
| OncoCyte Corporation | 49.29 Million USD | -242.986% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -3987.333% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -21102.306% |
| Purple Biotech Ltd. | 10 Million USD | -1590.005% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2822.312% |
| scPharmaceuticals Inc. | 57.26 Million USD | -195.288% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1264.907% |
| HilleVax, Inc. | 78.9 Million USD | -114.278% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -3248.218% |
| Tharimmune, Inc. | 1.81 Million USD | -9215.742% |
| Genprex, Inc. | 3.25 Million USD | -5095.888% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -523.493% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -3129.278% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -81980.097% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -47058.261% |
| OKYO Pharma Limited | 7.42 Million USD | -2178.514% |
| Savara Inc. | 37.19 Million USD | -354.627% |
| Curis, Inc. | 57.61 Million USD | -193.489% |
| Daré Bioscience, Inc. | 26.32 Million USD | -542.18% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -331.342% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -11609.488% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -712.167% |
| BeiGene, Ltd. | 2.23 Billion USD | 92.43% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -694.207% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 35.561% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -694.796% |
| Erasca, Inc. | 78.61 Million USD | -115.091% |
| bluebird bio, Inc. | 424.62 Million USD | 60.18% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -25704.576% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 91.054% |
| DBV Technologies S.A. | 42.8 Million USD | -295.058% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -25704.576% |
| Moderna, Inc. | 4.57 Billion USD | 96.302% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -2317.227% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -10110.447% |
| Molecular Templates, Inc. | 31.17 Million USD | -442.443% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -890.539% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 71.249% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -35.806% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -516.266% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -363.806% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -203.918% |
| MacroGenics, Inc. | 154.2 Million USD | -9.648% |
| RenovoRx, Inc. | 4.46 Million USD | -3686.05% |
| Adicet Bio, Inc. | 37.12 Million USD | -355.509% |
| Prime Medicine, Inc. | 60.78 Million USD | -178.192% |
| Aditxt, Inc. | 28.53 Million USD | -492.624% |
| Adagene Inc. | 45.16 Million USD | -274.336% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -93471.701% |
| Quantum-Si incorporated | 26.63 Million USD | -534.918% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 75.761% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -5457.55% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -47.08% |
| SciSparc Ltd. | 1.59 Million USD | -10500.94% |
| Vericel Corporation | 127.7 Million USD | -32.403% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2938.423% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -98.089% |
| Generation Bio Co. | 171.63 Million USD | 1.483% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1363.939% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -304.21% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 33.088% |
| Invivyd, Inc. | 51.71 Million USD | -226.968% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -83.834% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -2499.208% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -123.966% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -16460.725% |
| 2seventy bio, Inc. | 310.12 Million USD | 45.479% |
| ADMA Biologics, Inc. | 193.97 Million USD | 12.832% |
| Clene Inc. | 38.95 Million USD | -334.097% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -367.954% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 34.202% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4703.714% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 11.131% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1288.257% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 14.742% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1286.534% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -251.448% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -219.988% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 54.283% |
| Evaxion Biotech A/S | 17.61 Million USD | -859.757% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -5.068% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -10.379% |
| Trevena, Inc. | 48.26 Million USD | -250.348% |
| Surrozen, Inc. | 8.14 Million USD | -1975.936% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -682.982% |
| Cingulate Inc. | 10.36 Million USD | -1531.958% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -6048.545% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -353.408% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -4614.459% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1185.817% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 46.695% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -580.45% |
| Clearmind Medicine Inc. | 3.61 Million USD | -4583.785% |
| Kronos Bio, Inc. | 54.2 Million USD | -211.959% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -259.426% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -642.913% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -742.434% |
| Statera Biopharma, Inc. | 22.67 Million USD | -645.641% |
| ImmunityBio, Inc. | 1.09 Billion USD | 84.493% |
| Korro Bio, Inc. | 51.75 Million USD | -226.722% |
| Kineta, Inc. | 7.22 Million USD | -2241.249% |
| BioVie Inc. | 9.7 Million USD | -1642.762% |
| Codexis, Inc. | 49.94 Million USD | -238.536% |
| Celularity Inc. | 102.92 Million USD | -64.273% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -75.678% |
| Celcuity Inc. | 51.45 Million USD | -228.639% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -48882.601% |
| Cibus, Inc. | 206.11 Million USD | 17.966% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -298.081% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -541.957% |
| IN8bio, Inc. | 8.77 Million USD | -1827.554% |
| Kodiak Sciences Inc. | 213.59 Million USD | 20.837% |
| Annexon, Inc. | 47.11 Million USD | -258.854% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -88.835% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -75.45% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1135.189% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 93.505% |
| Eyenovia, Inc. | 19.78 Million USD | -754.816% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 4.518% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2101.341% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -601.627% |
| Arcellx, Inc. | 339.75 Million USD | 50.233% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1321.121% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 31.137% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1668.117% |
| Moolec Science SA | 13.94 Million USD | -1112.482% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -291.836% |
| Geron Corporation | 146.12 Million USD | -15.711% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -234.61% |
| Royalty Pharma plc | 6.29 Billion USD | 97.315% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -325.093% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -57332.593% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -6772.586% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 10.611% |
| Humacyte, Inc. | 114.67 Million USD | -47.445% |
| Structure Therapeutics Inc. | 29.05 Million USD | -482.028% |
| 89bio, Inc. | 59.96 Million USD | -181.982% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -538.949% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -14037.542% |
| Genelux Corporation | 8.42 Million USD | -1908.135% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -2366.234% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -24.036% |
| Notable Labs, Ltd. | 4.42 Million USD | -3719.404% |
| Liquidia Corporation | 73.13 Million USD | -131.186% |
| Mustang Bio, Inc. | 17.61 Million USD | -859.674% |
| Immunovant, Inc. | 48.95 Million USD | -245.389% |
| Quantum-Si incorporated | 26.63 Million USD | -534.918% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -340.521% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -5349.082% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -128.923% |
| Acasti Pharma Inc. | 11.55 Million USD | -1363.053% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -647.908% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -6120.005% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -358.511% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -12306.794% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2673.704% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -580.834% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -629.318% |
| PepGen Inc. | 34.63 Million USD | -388.248% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1292.334% |
| United Therapeutics Corporation | 1.18 Billion USD | 85.697% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -2321.034% |
| Solid Biosciences Inc. | 38.45 Million USD | -339.661% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1875.94% |
| Immuneering Corporation | 12 Million USD | -1308.061% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -53773.089% |
| Silo Pharma, Inc. | 1.56 Million USD | -10674.755% |
| Belite Bio, Inc | 4.21 Million USD | -3915.317% |
| XOMA Corporation | 145.58 Million USD | -16.146% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -6863.962% |
| Bionomics Limited | 10.15 Million USD | -1564.432% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -686.771% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -637.944% |
| uniQure N.V. | 624.01 Million USD | 72.904% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1091.159% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -93471.701% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 0.646% |
| Forte Biosciences, Inc. | 3.66 Million USD | -4512.248% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -64787.195% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -2406.077% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2101.341% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -872.703% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1499.972% |
| Altimmune, Inc. | 16.54 Million USD | -922.218% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 72.627% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -637.944% |
| Compugen Ltd. | 55.77 Million USD | -203.156% |
| Peak Bio, Inc. | 20.75 Million USD | -714.735% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -53.069% |
| Benitec Biopharma Inc. | 4.96 Million USD | -3307.598% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -7.122% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -124.925% |
| Zura Bio Limited | 21.29 Million USD | -694.125% |
| PolyPid Ltd. | 17.46 Million USD | -867.97% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -50.433% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -124.925% |
| Instil Bio, Inc. | 99.8 Million USD | -69.422% |
| argenx SE | 444.95 Million USD | 61.999% |
| Immunome, Inc. | 28.65 Million USD | -490.01% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1928.128% |
| Verona Pharma plc | 58.84 Million USD | -187.359% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1068.279% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1037.93% |
| CervoMed Inc. | 2.59 Million USD | -6413.925% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -3369.122% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1227.615% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1504.983% |
| Moolec Science SA | 13.94 Million USD | -1112.482% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -7115.051% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -204.135% |
| AnaptysBio, Inc. | 364.28 Million USD | 53.585% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1314.227% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1233.057% |
| NeurAxis, Inc. | 1.91 Million USD | -8739.941% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -334.353% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1168.169% |
| Achilles Therapeutics plc | 19.08 Million USD | -785.865% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1068.279% |
| 180 Life Sciences Corp. | 5.38 Million USD | -3038.638% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -616.827% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -642.913% |
| Nutriband Inc. | 1.07 Million USD | -15571.705% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -452.601% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1065.219% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 57.863% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -420.694% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1195.76% |
| Palisade Bio, Inc. | 2.73 Million USD | -6073.238% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -3118.827% |
| Beam Therapeutics Inc. | 478.38 Million USD | 64.655% |
| Neurogene Inc. | 36.54 Million USD | -362.626% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 57.511% |
| AEON Biopharma, Inc. | 159.88 Million USD | -5.751% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -254.848% |
| Sesen Bio, Inc. | 30.98 Million USD | -445.717% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -551.304% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -2124.154% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 13.617% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 11.961% |
| Athira Pharma, Inc. | 30.05 Million USD | -462.548% |
| Vaccinex, Inc. | 5.94 Million USD | -2745.591% |
| HCW Biologics Inc. | 15.05 Million USD | -1023.343% |
| XOMA Corporation | 145.58 Million USD | -16.146% |
| Nektar Therapeutics | 267.04 Million USD | 36.683% |
| Arvinas, Inc. | 644.6 Million USD | 73.769% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -853.498% |
| Merus N.V. | 102.15 Million USD | -65.525% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -15.535% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -77.76% |
| Rezolute, Inc. | 11.73 Million USD | -1340.983% |
| Clene Inc. | 38.95 Million USD | -334.097% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -5838.266% |
| BeyondSpring Inc. | 48.26 Million USD | -250.297% |
| Synlogic, Inc. | 32.89 Million USD | -414.014% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1057.086% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -10247.919% |
| Peak Bio, Inc. | 20.75 Million USD | -714.735% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -166.448% |
| Krystal Biotech, Inc. | 39.71 Million USD | -325.757% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 55.107% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -69.817% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -38974.38% |
| MannKind Corporation | 721.36 Million USD | 76.56% |
| Ikena Oncology, Inc. | 22.33 Million USD | -657.041% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -8005.705% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -64.816% |
| Gossamer Bio, Inc. | 249.14 Million USD | 32.134% |
| CohBar, Inc. | 1.03 Million USD | -16258.241% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1481.86% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -787.678% |
| Legend Biotech Corporation | 589.93 Million USD | 71.338% |
| Mural Oncology plc | 37.92 Million USD | -345.805% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -27.48% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -7266.472% |
| Disc Medicine, Inc. | 22.87 Million USD | -639.169% |
| Champions Oncology, Inc. | 28.03 Million USD | -503.121% |
| REGENXBIO Inc. | 262.22 Million USD | 35.52% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -4933.262% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1249.011% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1158.857% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -697.383% |
| Vaxart, Inc. | 34.02 Million USD | -396.943% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -729.284% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -492.618% |
| Cellectis S.A. | 249.57 Million USD | 32.251% |
| Longeveron Inc. | 5.33 Million USD | -3068.166% |
| Repare Therapeutics Inc. | 41.81 Million USD | -304.326% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 92.97% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -180.09% |
| Revolution Medicines, Inc. | 262.39 Million USD | 35.561% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -7924.917% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1860.179% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1332.802% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1104.052% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -7760.762% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 96.717% |
| Denali Therapeutics Inc. | 122.96 Million USD | -37.509% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2938.423% |
| Veru Inc. | 32.81 Million USD | -415.303% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -2361.566% |
| Cingulate Inc. | 10.36 Million USD | -1531.958% |
| Passage Bio, Inc. | 39.26 Million USD | -330.658% |
| Context Therapeutics Inc. | 4.19 Million USD | -3933.79% |
| Exicure, Inc. | 8.54 Million USD | -1877.834% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -473.014% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1512.483% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -667.139% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -3.742% |
| Nuvalent, Inc. | 31.82 Million USD | -431.33% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2557.889% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -168.295% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -839.361% |
| OmniAb, Inc. | 87.4 Million USD | -93.461% |
| Anew Medical, Inc. | 8.24 Million USD | -1951.555% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -341.601% |
| Lipocine Inc. | 2.63 Million USD | -6325.108% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -543.594% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -320.484% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -534.66% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -96.259% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -3030.624% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -104.34% |
| Ocugen, Inc. | 23.98 Million USD | -605.02% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -264.352% |
| Q32 Bio Inc. | 233.12 Million USD | 27.471% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1765.045% |
| Alumis Inc. Common Stock | 53.5 Million USD | -216.035% |
| Equillium, Inc. | 27.95 Million USD | -504.804% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 18.155% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2905.066% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2656.985% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -7.474% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -143.523% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1595.224% |
| Dominari Holdings Inc. | 4.63 Million USD | -3548.004% |
| Edesa Biotech, Inc. | 1.84 Million USD | -9081.234% |
| vTv Therapeutics Inc. | 29.56 Million USD | -471.871% |
| Bio-Techne Corporation | 744.34 Million USD | 77.284% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -34.089% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 50.912% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -316.722% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -483.918% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -83.072% |
| Nkarta, Inc. | 105.6 Million USD | -60.118% |
| BioCardia, Inc. | 4.59 Million USD | -3583.769% |
| Iterum Therapeutics plc | 32.66 Million USD | -417.681% |